Submission declined on 28 December 2025 by HurricaneZeta (talk). This draft is not written from a neutral point of view. Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove: promotional language: see Words to watch; personal commentary: opinions or direct addresses to the reader; informal language. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that: provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles; are reliable: from reputable outlets with editorial oversight; are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content. Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by HurricaneZeta 7 months ago. Last edited by OpalYosutebito 2 months ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

• Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. Mb plasmidsaurus (talk) 15:49, 28 December 2025 (UTC)

Plasmidsaurus is an American biotechnology company based in South San Francisco, California. The company provides DNA and RNA sequencing-as-a-service. It is best known for democratizing access to whole-plasmid sequencing and RNA-Seq, a model that has disrupted the traditional sequencing market and reportedly caused shifts in how academic core facilities operate.^[1]

The company was founded in 2021 by Mark Budde to address the logistical and cost barriers associated with verifying plasmid constructs in synthetic biology research. Initially bootstrapping its operations, the company grew by utilizing the Oxford Nanopore Technologies platform to offer low-cost verification of DNA materials.

In 2024, Plasmidsaurus formally expanded its strategic collaboration with Oxford Nanopore. The multi-million dollar agreement established Plasmidsaurus as a key commercial user of the nanopore platform, aiming to displace traditional Sanger sequencing in specific sectors of the synthetic biology market.^[2]

Plasmidsaurus utilizes a "sequencing-as-a-service" model where researchers mail samples for overnight processing. The company's primary technology is long-read nanopore sequencing, which allows for the resolution of complex DNA structures (such as repetitive regions) that are often difficult to sequence with short-read methods.

The company's approach has been cited in methodological papers for reducing the effective cost of whole-plasmid sequencing to approximately $15 per sample, significantly lower than the aggregated cost of multiple Sanger reactions required to cover the same sequence length.^[3]

In late 2025, the company launched an RNA-Seq service. Industry reporting by GenomeWeb noted that the service's low cost and rapid turnaround time created "unease" among traditional academic genomic core facilities, which typically operate on longer timelines and higher price points.^[1]

The company operates in a market historically reliant on Sanger sequencing for quality control. In 2024, a study highlighted in Nature revealed that nearly half of commercially provided plasmids contained significant errors, such as truncated sequences or incorrect backbones, which legacy methods often missed.^[4] Plasmidsaurus capitalized on this reliability gap by offering long-read sequencing that could resolve the full length of plasmid DNA.

Category:Biotechnology companies of the United States Category:Companies based in South San Francisco Category:Companies founded in 2021 Category:Genomics